ArticleViruses2025
Attenuation of a Novel Goose Parvovirus Strain NMG21 via Serial Cell Passage.
Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oral immunization with recombinant Lactococcus lactis expressing VP3 and VP3-IFNα fusion protein protects ducklings against novel goose parvovirus infection.Poultry science · 2026Article
- Development and validation of a quadruplex qPCR assay for simultaneous detection of GPV, GoCV, TMUV, and GAstV-Ⅱ in geese.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The novel goose parvovirus (N-GPV), responsible for beak atrophy and dwarfism syndrome (BADS), has caused significant economic losses in China's duck-raising industry. In this study, a highly virulent N-GPV strain NMG21 was serially passaged in duck embryo fibroblast cells (DEFs). The virus titers and virulence of selected passages were evaluated in 1-day-old ducklings. An increased virus titer was observed at the 5th passage (P5). Compared with the parent strain NMG21, the P35 (NMG21-35 strain) has a clear decrease in pathogenicity for ducklings, with less tissue damage. The NMG21-35 also exhibited relatively lower tissue replication rates and higher antibody levels. Collectively, the virulence of N-GPV strain NMG21 was reduced via serial passage in DEFs for 35 passages. Our research successfully prepared a N-GPV attenuated variant which might serve as a potential live vaccine candidate against N-GPV infection. Developing a live attenuated vaccine candidate against N-GPV infection in China is crucial for mitigating the economic impact of N-GPV on the duck industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.